Pharmacokinetics of levosimendan in severe patients with continuous blood purification

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053060

Enrollment

Unknown

Registered

2021-11-10

Start date

2021-12-30

Completion date

Unknown

Last updated

2022-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac failure

Interventions

CRRT group:Intravenous infusion of levosimendan

Non-CRRT group:Intravenous infusion of levosimendan

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged older than 18 years; 2.Relatively stable circulation (defined as MAP above 65mmHg with norepinephrine <=0.1ug/kg.min or dopamine <= 5ug/kg.min); 3.Signing informed consent; 4.Abnormal cardiac function (EF < 50%).

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating subjects; 2.A person who has decided to discontinue or discontinue artificial life support, i.e. to give up medical treatment; 3.Levosimendan has been used within the past 30 days; 4.A history of levosimendan allergy; 5.Previous acute coronary syndrome, tip torsional ventricular tachycardia; 6.Have a history of chronic kidney disease or chronic renal insufficiency.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic indices of levosimendan;Pharmacokinetic indices of OR-1855 and OR-1896;Cardiac function index;	—

Countries

China

Contacts

Public ContactPei Fei

The First Affiliated Hospital, Sun Yat-Sen University

Wilsonsong2017@163.com+86 18907195976

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026